82.315  0.165 (0.2%)		01-02 15:59
Open: 82.39 High: 82.39 Volume: 4,913		Pre. Close: 82.15 Low: 81.5701 Market Cap: 268(M)

Short term
Mid term
Targets	6-month :	98.31	1-year :	114.82
Resists	First :	84.16	Second :	98.31
Pivot price	81.98
Supports	First :	81.3	Second :	79.54
MAs	MA(5) :	82.82	MA(20) :	81.7
	MA(100) :	74.54	MA(250) :	68.67
MACD	MACD :	1	Signal :	1.1
%K %D	K(14,3) :	58.7	D(3) :	68.5
RSI	RSI(14): 56.7
52-week	High :	84.16	Low :	54.52

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PBE ] has closed below upper band by 44.2%. Bollinger Bands are 9.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	82.58 - 83.13	83.13 - 83.62
Low:	80.19 - 80.9	80.9 - 81.55
Close:	81.23 - 82.34	82.34 - 83.34

PBE is not a pure-play biotech fund, it goes beyond the scope of pure biotech firms and includes companies that benefit significantly from advances in biotech and genetic engineering. This causes PBE to differ from other biotech ETFs, therefore, it is important to note the funds portfolio before investing. Moreover, far from a plain-vanilla approach, PBE's underlying index uses a multifactor system (price momentum, earnings momentum, quality: ROE, asset turnover, FCF margin), management action, and value) to select 30 US stocks and weights them in tiers. The tiered weighting scheme creates a small-cap tilt. Top-ranked larger stocks receive 40% of index weight while the top-ranked smaller stocks are given 60%. The approach produces a unique portfolio of biotech and peripheral-industry companies. The fund is rebalanced and reconstituted quarterly starting each February. Prior to August 28, 2023, the fund traded under the name Invesco Dynamic Biotechnology & Genome ETF.

Thu, 01 Jan 2026
Institution Moves: Can Invesco Biotechnology Genome ETF stock sustain breakout momentum - Share Buyback & Fast Gain Swing Trade Alerts - moha.gov.vn

Fri, 19 Dec 2025
INVESCO NASDAQ BIOTECHNOLOGY ETF To Go Ex-Dividend On December 22nd, 2025 With 0.0906 USD Dividend Per Share - 富途牛牛

Thu, 02 Oct 2025
The Best Biotech ETFs to Buy - Kiplinger

Mon, 29 Sep 2025
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Yahoo Finance

Wed, 13 Aug 2025
7 Best Biotech ETFs to Buy Now - US News Money

Fri, 01 Aug 2025
The best and worst funds in July . - investments.halifax.co.uk

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.